Intellia Therapeutics ($NTLA): FDA Accepts BLA with Priority Review (PDUFA March 10, 2027), No AdCom Planned & Fully Funded Past 2028 via $400M OrbiMed Facility

Intellia Therapeutics ($NTLA): FDA Accepts BLA with Priority Review (PDUFA March 10, 2027), No AdCom Planned & Fully Funded Past 2028 via $400M OrbiMed Facility Intellia just cleared two massive fundamental hurdles in rapid succession: The FDA officially accepted the Biologics License Application (BLA) for lonvo-z (HAE) under Priority Review, set a firm PDUFA date for March 10, 2027, and confirmed that no Advisory Committee (AdCom) meeting is currently planned. In tandem, a $400M non-dilutive senior secured credit facility with OrbiMed secures operational runway well past commercial launch into 2028 without diluting shareholders. Regulatory Breakthrough: FDA BLA Acceptance & Priority Review BLA Accepted: The FDA has formally accepted the BLA for lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE). Priority Review Granted: Accelerates the standard 10-month review down to 6 months, establishing a target PDUFA action date of March 10, 2027. No Advisory Committee (AdCom): The FDA notified Intellia that it does not currently plan to convene an external advisory panel. For a novel gene-editing platform, skipping an AdCom is an exceptionally strong vote of confidence in the clarity of the Phase 3 safety and efficacy package. Historical Milestone: Upon approval, lonvo-z will become the world's first approved in vivo CRISPR-based medicine and the only one-time treatment option for HAE. Clinical Foundation (Phase 3 HAELO Trial) The BLA submission is anchored by Phase 3 trial results published in the New England Journal of Medicine (NEJM): 87% reduction in mean monthly attack rates compared to placebo (p < 0.0001) during the 24-week evaluation period (weeks 5 to 28). 62% of patients were entirely attack-free and off chronic prophylactic therapies for the full 6-month evaluation window (vs. 11% in placebo). Safety Profile: All treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1/2), primarily consisting of mild infusion-related reactions, fatigue, and transient headaches. Zero serious adverse events (SAEs) were reported in the lonvo-z arm. Pipeline Momentum: nex-z in ATTR Amyloidosis Phase 3 Resumption: Patient screening and enrollment are fully reinitiated across both MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) trials. Enrollment Target: Patient recruitment for MAGNITUDE-2 remains on track to complete in H2 2026. Safety Mechanism Resolved: Comprehensive genomic analysis across 600+ patient samples linked isolated liver transaminase spikes to a specific HLA allele. Intellia has implemented upfront HLA-genotyping protocols for clinical screening, turning an unpredictable clinical question mark into a standardized biomarker protocol. Balance Sheet & Non-Dilutive Runway Cash Position: Ended Q2 2026 with $628.4M in cash, cash equivalents, and marketable securities. $400M OrbiMed Credit Facility: Senior secured term loan providing non-dilutive capital. $75M was funded immediately at closing, with up to $225M available across 5 tranches tied to lonvo-z milestones, plus an additional $100M accordion option. Runway into 2028: Existing resources fully fund operations at least into 2028—well beyond the anticipated H1 2027 US commercial launch. This guidance excludes all future commercial revenue generated by lonvo-z. Key Milestones Ahead H2 2026: Completion of patient enrollment in the MAGNITUDE-2 Phase 3 trial (nex-z). Late 2026 / Early 2027: Completion of commercial launch buildout (field medical, market access, and strategic account integration). March 10, 2027: FDA PDUFA target action date for lonvo-z. H1 2027: Projected US commercial launch. Disclaimer: Not financial advice. For informational and research purposes only.